Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.415
-0.135 (-8.71%)
Mar 31, 2025, 1:23 PM EDT - Market open
Allogene Therapeutics Stock Forecast
ALLO's stock price has decreased by -65.25% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Allogene Therapeutics stock have an average target of 9.66, with a low estimate of 4.60 and a high estimate of 14. The average target predicts an increase of 582.69% from the current stock price of 1.42.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +465.37% | Mar 19, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +889.40% | Mar 14, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +606.71% | Mar 14, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +253.36% | Mar 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $9 | Buy | Maintains | $11 → $9 | +536.04% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
46.38K
from 22.00K
Increased by 110.82%
Revenue Next Year
41.00K
from 46.38K
Decreased by -11.59%
EPS This Year
-1.20
from -1.32
EPS Next Year
-1.26
from -1.20
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 210,000 | 210,000 | 147.2M | ||
| Avg | 46,379 | 41,004 | 55.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 854.5% | 352.8% | 358,938.1% | ||
| Avg | 110.8% | -11.6% | 135,759.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.85 | -0.67 | -0.99 | ||
| Avg | -1.20 | -1.26 | -1.37 | ||
| Low | -1.53 | -1.81 | -2.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.